149 related articles for article (PubMed ID: 38476237)
1. Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-α.
Spencer EA; Dubinsky MC; Kamm MA; Chaparro M; Gionchetti P; Rizzello F; Gisbert JP; Wright EK; Schulberg JD; Hamilton AL; McGovern DPB; Dervieux T
Front Immunol; 2024; 15():1342477. PubMed ID: 38476237
[TBL] [Abstract][Full Text] [Related]
2. Influence of HLADQA1*05 Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study.
Fuentes-Valenzuela E; García-Alonso FJ; Maroto-Martín C; Juan Casamayor L; Garrote JA; Almendros Muñoz R; De Prado Á; Vara Castrodeza A; Marinero MÁ; Calleja Carbajosa R; Barrio J
Inflamm Bowel Dis; 2023 Oct; 29(10):1586-1593. PubMed ID: 36617284
[TBL] [Abstract][Full Text] [Related]
3. HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease.
Sazonovs A; Kennedy NA; Moutsianas L; Heap GA; Rice DL; Reppell M; Bewshea CM; Chanchlani N; Walker GJ; Perry MH; McDonald TJ; Lees CW; Cummings JRF; Parkes M; Mansfield JC; Irving PM; Barrett JC; McGovern D; Goodhand JR; Anderson CA; Ahmad T;
Gastroenterology; 2020 Jan; 158(1):189-199. PubMed ID: 31600487
[TBL] [Abstract][Full Text] [Related]
4. HLA-DQA1*05 Was Not Associated With Primary Nonresponse or Loss of Response to First Anti-TNF in Real-World Inflammatory Bowel Disease Patients.
Pascual-Oliver A; Casas-Deza D; Cuarán C; García-López S; Corsino-Roche P; Sierra-Moros E; Olier-Martínez P; González-Tarancón R; Vicente-Lidón R
Inflamm Bowel Dis; 2024 Jun; 30(6):922-929. PubMed ID: 37462462
[TBL] [Abstract][Full Text] [Related]
5. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
[TBL] [Abstract][Full Text] [Related]
6. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
[TBL] [Abstract][Full Text] [Related]
7. Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment.
Brandse JF; Vos LM; Jansen J; Schakel T; Ponsioen CI; van den Brink GR; D'Haens GR; Löwenberg M
J Crohns Colitis; 2015 Nov; 9(11):973-81. PubMed ID: 26116557
[TBL] [Abstract][Full Text] [Related]
8. Distinct Association of Serum Vitamin D Concentration with Disease Activity and Trough Levels of Infliximab and Adalimumab during Inflammatory Bowel Disease Treatment.
Mechie NC; Mavropoulou E; Ellenrieder V; Kunsch S; Cameron S; Amanzada A
Digestion; 2020; 101(6):761-770. PubMed ID: 31536991
[TBL] [Abstract][Full Text] [Related]
9. Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials.
Brun MK; Gehin JE; Bjørlykke KH; Warren DJ; Klaasen RA; Sexton J; Sandanger Ø; Kvien TK; Mørk C; Jahnsen J; Bolstad N; Jørgensen KK; Haavardsholm EA; Goll GL; Syversen SW
Lancet Rheumatol; 2024 Apr; 6(4):e226-e236. PubMed ID: 38402891
[TBL] [Abstract][Full Text] [Related]
10. One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective study.
Cheli S; Savino D; De Silvestri A; Norsa L; Sansotta N; Penagini F; Dilillo D; Panceri R; Cattaneo D; Clementi E; Zuin G
Pharmacogenomics J; 2023 Sep; 23(5):112-118. PubMed ID: 37016150
[TBL] [Abstract][Full Text] [Related]
11. Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study.
Chanchlani N; Lin S; Auth MK; Lee CL; Robbins H; Looi S; Murugesan SV; Riley T; Preston C; Stephenson S; Cardozo W; Sonwalkar SA; Allah-Ditta M; Mansfield L; Durai D; Baker M; London I; London E; Gupta S; Di Mambro A; Murphy A; Gaynor E; Jones KDJ; Claridge A; Sebastian S; Ramachandran S; Selinger CP; Borg-Bartolo SP; Knight P; Sprakes MB; Burton J; Kane P; Lupton S; Fletcher A; Gaya DR; Colbert R; Seenan JP; MacDonald J; Lynch L; McLachlan I; Shields S; Hansen R; Gervais L; Jere M; Akhtar M; Black K; Henderson P; Russell RK; Lees CW; Derikx LAAP; Lockett M; Betteridge F; De Silva A; Hussenbux A; Beckly J; Bendall O; Hart JW; Thomas A; Hamilton B; Gordon C; Chee D; McDonald TJ; Nice R; Parkinson M; Gardner-Thorpe H; Butterworth JR; Javed A; Al-Shakhshir S; Yadagiri R; Maher S; Pollok RCG; Ng T; Appiahene P; Donovan F; Lok J; Chandy R; Jagdish R; Baig D; Mahmood Z; Marsh L; Moss A; Abdulgader A; Kitchin A; Walker GJ; George B; Lim YH; Gulliver J; Bloom S; Theaker H; Carlson S; Cummings JRF; Livingstone R; Beale A; Carter JO; Bell A; Coulter A; Snook J; Stone H; Kennedy NA; Goodhand JR; Ahmad T;
Aliment Pharmacol Ther; 2022 Oct; 56(8):1250-1263. PubMed ID: 36039036
[TBL] [Abstract][Full Text] [Related]
12. The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease.
Seow CH; Leung Y; Vande Casteele N; Ehteshami Afshar E; Tanyingoh D; Bindra G; Stewart MJ; Beck PL; Kaplan GG; Ghosh S; Panaccione R
Aliment Pharmacol Ther; 2017 May; 45(10):1329-1338. PubMed ID: 28318043
[TBL] [Abstract][Full Text] [Related]
13. Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies.
Bitoun S; Hässler S; Ternant D; Szely N; Gleizes A; Richez C; Soubrier M; Avouac J; Brocq O; Sellam J; de Vries N; Huizinga TWJ; Jury EC; Manson JJ; Mauri C; Matucci A; Hacein Bey Abina S; Mulleman D; Pallardy M; Broët P; Mariette X;
JAMA Netw Open; 2023 Jul; 6(7):e2323098. PubMed ID: 37436748
[TBL] [Abstract][Full Text] [Related]
14. High Anti-Infliximab Antibody Titers Do Not Impact Response to Subsequent Adalimumab Treatment in Inflammatory Bowel Diseases.
Sasson AN; Ananthakrishnan AN
Dig Dis Sci; 2022 Jul; 67(7):3124-3128. PubMed ID: 34117949
[TBL] [Abstract][Full Text] [Related]
15. Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort.
Salvador-Martín S; Zapata-Cobo P; Velasco M; Palomino LM; Clemente S; Segarra O; Sánchez C; Tolín M; Moreno-Álvarez A; Fernández-Lorenzo A; Pérez-Moneo B; Loverdos I; Navas López VM; Millán A; Magallares L; Torres-Peral R; García-Romero R; Pujol-Muncunill G; Merino-Bohorquez V; Rodríguez A; Salcedo E; López-Cauce B; Marín-Jiménez I; Menchén L; Laserna-Mendieta E; Lucendo AJ; Sanjurjo-Sáez M; López-Fernández LA
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675312
[TBL] [Abstract][Full Text] [Related]
16. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.
Papamichael K; Chachu KA; Vajravelu RK; Vaughn BP; Ni J; Osterman MT; Cheifetz AS
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1580-1588.e3. PubMed ID: 28365486
[TBL] [Abstract][Full Text] [Related]
17. Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis Factor.
Vande Casteele N; Abreu MT; Flier S; Papamichael K; Rieder F; Silverberg MS; Khanna R; Okada L; Yang L; Jain A; Cheifetz AS
Clin Gastroenterol Hepatol; 2022 Feb; 20(2):465-467.e2. PubMed ID: 33421628
[TBL] [Abstract][Full Text] [Related]
18. INFLIXIMAB AND ADALIMUMAB SERUM TROUGH CONCENTRATIONS THRESHOLD ASSOCIATED WITH DEEP REMISSION IN INFLAMMATORY BOWEL DISEASE.
Pascual-Marmaneu Ó; Belles-Medall MD; Ferrando-Piqueres R; Almela-Notari P; Mendoza-Aguilera M; Álvarez-Martín T
Farm Hosp; 2021 Aug; 45(5):225-233. PubMed ID: 34806581
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease.
Stallhofer J; Guse J; Kesselmeier M; Grunert PC; Lange K; Stalmann R; Eckardt V; Stallmach A
Int J Colorectal Dis; 2023 Feb; 38(1):54. PubMed ID: 36840779
[TBL] [Abstract][Full Text] [Related]
20. Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.
Roblin X; Williet N; Boschetti G; Phelip JM; Del Tedesco E; Berger AE; Vedrines P; Duru G; Peyrin-Biroulet L; Nancey S; Flourie B; Paul S
Gut; 2020 Jul; 69(7):1206-1212. PubMed ID: 31980448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]